Cardiome enters into commercialization deal with AOP Orphan for Aggrastat
Both the firms have not disclosed the details of the agreement, under which AOP Orphan has agreed to specific annual commercial goals for AGGRASTAT. The deal will see
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
SUGARDOWN is Boston Therapeutics’ currently marketed dietary supplement that is intended to support healthy blood sugar. In addition, clinical studies indicate that SUGARDOWN can maintain healthy glucose levels
At present, Entyvio is approved for inducing and maintaining clinical response and remission, improving endoscopic appearance of the mucosa. The drug secured the approval to achieve corticosteroid-free remission